
    
      High dose proton pump inhibitor (PPI) has been proved beneficial and it improved efficacy
      when combined with chemotherapy in preclinical and clinical trials.This study was designed to
      explore whether adding a proton pump inhibitor into docetaxel and cisplatin chemotherapy
      improves efficacy and does not affect tolerability in metastatic breast cancer.
    
  